tci Medicare Compliance & Reimbursement - 2004 Issue 31
Enforcement Watch: Firms Should Be Vigilant On Reporting Drug Prices
Subscribe or sign in to view the full article.
Article Overview
This article covers a federal enforcement action involving a pharmaceutical company, its settlement with the Department of Justice, and related compliance obligations tied to drug price reporting and government health care programs. It is aimed at readers who follow health care fraud enforcement, pharmaceutical compliance, and reimbursement-related reporting requirements. The article also notes the role of a corporate integrity agreement, program exclusion, and broader government scrutiny of pricing information submitted for public programs.
Why This Topic Matters
It highlights how enforcement actions can affect pharmaceutical manufacturers, their sales practices, and their reporting obligations to government payers. Readers interested in compliance, audits, and anti-kickback exposure will find the article relevant.
What You Will Learn
- How a federal settlement can intersect with pharmaceutical pricing and Medicaid-related reporting
- Why compliance issues in sales and marketing practices draw government attention
- What types of oversight measures may follow a health care fraud resolution
- How enforcement actions can affect participation in federal health care programs
Who Should Read This
- Pharmaceutical compliance professionals
- Health care attorneys
- Medical billing and coding compliance teams
- Revenue integrity professionals
- Government program integrity analysts
Subscribe or sign in to view the full article.
Thank you for choosing Find-A-Code, please Sign In to remove ads.


Quick, Current, Complete - www.findacode.com